SCHEMBL1922500

SCHEMBL1922500

CCOCOc1ccc2oc(B(O)O)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
HSD17B10 Q99714 2/20 0.44
MGLL Q99685 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAOB P27338 5/20 0.37
MAOA P21397 2/20 0.36
CA12 O43570 4/20 0.35
CA9 Q16790 4/20 0.35
CA1 P00915 3/20 0.35
CA4 P22748 2/20 0.35
CA6 P23280 2/20 0.35
CA5A P35218 2/20 0.35
CA7 P43166 2/20 0.35
CA14 Q9ULX7 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
CYP1A2 P05177 1/20 0.35
ALDH1A1 P00352 5/20 0.34
HPGD P15428 3/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10025750 0.90 MAOB (0.36) KDM4EHSD17B10MGLLTDP1MAOB
SCHEMBL17401003 0.88 KDM4E (0.49) KDM4EHSD17B10MGLLTDP1MAOB
SCHEMBL13457571 0.88 MAOB (0.38) KDM4EHSD17B10MAOBMAOACA12
SCHEMBL17541501 0.86 KDM4E (0.46) KDM4EHSD17B10MGLLTDP1MAOB
SCHEMBL12269272 0.83 MAOB (0.51) KDM4EHSD17B10MGLLTDP1MAOB
SCHEMBL29957761 0.83 MAOB (0.48) KDM4EHSD17B10MGLLTDP1MAOB
SCHEMBL20503675 0.81 MAOB (0.39) KDM4EHSD17B10MAOBMAOACA12
SCHEMBL18715093 0.79 MAOB (0.39) KDM4EHSD17B10MAOBMAOACA12
SCHEMBL29000615 0.78 KDM4E (0.42) KDM4EHSD17B10MGLLTDP1MAOB
SCHEMBL2963271 0.77 KDM4E (0.53) KDM4EHSD17B10MGLLTDP1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309267-B2 Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits ASTRAZENECA AB (SE) 2016-04-12 US claimed
US-20140296534-A1 COMPOUNDS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB (SE) 2014-10-02 US claimed
US-20120264943-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits ASTRAZENECA AB (SE) 2012-10-18 US claimed
EP-2328891-A1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS AstraZeneca AB (SE) 2011-06-08 EP claimed
WO-2010024769-A1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB (SE) 2010-03-04 WO claimed
US-20100056796-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits ASTRAZENECA AB (SE) 2010-03-04 US claimed
US-20210346526-A1 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION FIVE ELEVEN PHARMA INC. 2021-11-11 US disclosed
US-11071794-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application FIVE ELEVEN PHARMA INC. (US) 2021-07-27 US disclosed
US-10912849-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application FIVE ELEVEN PHARMA INC. (US) 2021-02-09 US disclosed
US-20200230263-A1 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION FIVE ELEVEN PHARMA INC. (US) 2020-07-23 US disclosed
EP-2328891-B1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB (SE) 2017-04-05 EP disclosed
EP-2328891-B1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB (SE) 2017-04-05 EP disclosed
US-9309267-B2 Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits ASTRAZENECA AB (SE) 2016-04-12 US disclosed
US-8193363-B2 Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits ASTRAZENECA AB (SE) 2012-06-05 US disclosed
EP-2328891-A1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS AstraZeneca AB (SE) 2011-06-08 EP disclosed
WO-2010024769-A1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB (SE) 2010-03-04 WO disclosed
WO-2010024769-A1 NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB (SE) 2010-03-04 WO disclosed
US-20100056796-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits ASTRAZENECA AB (SE) 2010-03-04 US disclosed
US-20100056796-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits ASTRAZENECA AB (SE) 2010-03-04 US disclosed
US-20100056796-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits ASTRAZENECA AB (SE) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11071794-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application SLC18A2, SLC6A3, SLC6A2 KDM4E 3906/4885HSD17B10 616/4885MGLL 2993/4885
US-20200230263-A1 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION SLC18A2, SLC6A3, SLC6A2 KDM4E 3635/4885HSD17B10 631/4885MGLL 3014/4885
US-20210346526-A1 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION SLC18A2, SLC6A3, SLC6A2 KDM4E 3635/4885HSD17B10 631/4885MGLL 3014/4885
US-10912849-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application SLC18A2, SLC6A3, SLC6A2 KDM4E 3906/4885HSD17B10 616/4885MGLL 2993/4885
US-20100056796-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits APP, PSEN1, PSEN2 KDM4E 4113/4885HSD17B10 2119/4885MGLL 2296/4885
US-20140296534-A1 COMPOUNDS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS APP, PSEN1, PSEN2 KDM4E 4113/4885HSD17B10 2119/4885MGLL 2296/4885
US-20120264943-A1 Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits APP, PSEN1, PSEN2 KDM4E 4113/4885HSD17B10 2119/4885MGLL 2296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.